Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
1(33.3%)
Phase 1
1(33.3%)
Phase 3
1(33.3%)
3Total
Early Phase 1(1)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02560220Phase 1Completed

MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients

Role: collaborator

NCT02944084Early Phase 1Completed

Absorption and Excretion Kinetics of the Bioactive Ingredients of Rice Bran Extract

Role: collaborator

NCT00543881Phase 3Completed

Telemedical Interventional Monitoring in Heart Failure

Role: collaborator

NCT01624181Completed

Fast Identification of Pathogen in the Setting of Hospital-acquired Pneumonia Using Ion Mobility Spectrometry

Role: collaborator

All 4 trials loaded